2025-11-24 - Analysis Report
Okay, here's a comprehensive report on Johnson & Johnson (JNJ), based on the data you provided.

**1. Return Rate Analysis**

*   **Ticker:** JNJ (Johnson & Johnson)
*   **Overview:** Johnson & Johnson is a multinational corporation that develops and manufactures pharmaceuticals, medical devices, and consumer packaged goods.
*   **JNJ Cumulative Return:** 56.61%
*   **S&P 500 (VOO) Cumulative Return:** 94.64%
*   **Divergence:**
    *   Current: -38.0
    *   Relative Divergence: 33.3

**Analysis of Return Rates:** JNJ has significantly underperformed the S&P 500 over the period analyzed. The current divergence of -38% indicates that JNJ's returns have lagged behind the market by a substantial margin. A relative divergence of 33.3 suggests that the current underperformance is closer to the lower end of its historical divergence range.

**Alpha, Beta Analysis**

| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|-------|
| 2015-2017  | 26.0% | 66.8% | -2.0% | 0.0 | 336.6 |
| 2016-2018  | 14.0% | 10.7% | -1.0% | 0.1 | 310.9 |
| 2017-2019  | 20.0% | 71.5% | -2.0% | 0.4 | 351.4 |
| 2018-2020  | 19.0% | 79.2% | -4.0% | 0.4 | 379.2 |
| 2019-2021  | 33.0% | 79.2% | -14.0% | 0.5 | 412.2 |
| 2020-2022  | 8.0% | 79.6% | 9.0% | 0.4 | 425.6 |
| 2021-2023  | -19.0% | 79.6% | -21.0% | 0.3 | 377.6 |
| 2022-2024  | -32.0% | 79.6% | -53.0% | 0.3 | 348.4 |
| 2023-2025  | 28.0% | 79.6% | -32.0% | 0.1 | 491.3 |

**Analysis of Alpha/Beta:**

*   **Alpha:** JNJ frequently exhibits negative alpha, meaning it has generally underperformed its expected return based on its beta.  The 2020-2022 period shows a positive alpha, indicating outperformance during that period. However, recent years show significant negative alpha.
*   **Beta:** The beta values are generally low (around 0.1 to 0.5), indicating that JNJ's price is less volatile than the overall market. It implies that JNJ is less sensitive to market movements.
*   **CAGR:** CAGR (Compound Annual Growth Rate) fluctuates over different periods.
*   **MDD:** MDD (Maximum Drawdown) is relatively high, particularly in recent years, indicating periods of significant losses.
*   **Cap:** Market Cap is generally increasing throughout the historical period shown.

**2. Stock Price Fluctuations**

*   **Current Close:** 203.90
*   **Previous Close:** 203.07
*   **Change:** 0.41
*   **5-day SMA:** 201.81
*   **20-day SMA:** 192.43
*   **60-day SMA:** 186.46

**Analysis of Stock Price:** The current stock price is above all three simple moving averages (5-day, 20-day, and 60-day SMA). This suggests a short-term bullish trend. The fact that the 5-day SMA is above the 20-day SMA, which is above the 60-day SMA, further supports this observation. The recent price change of 0.41 suggests a small upward movement, but the provided details don't indicate a sharp rebound or decline.

**3. RSI, PPO Index, and Expected Return**

*   **Market Risk Indicator (MRI):** 0.8 (Medium Investment Recommended)
*   **RSI:** 96.52 (Overbought)
*   **PPO:** 0.66
*   **Hybrid Signal:** cash_0%_Buy 100% of cash (5 shares - Very Safe - MRI:0.90) (Cash Ratio: 0% on 2025-11-12)
*   **Recent (20 days) relative divergence change:** 12.1 (+) (Short-term rise)
*   **Expected Return (%):** -44.8

**Analysis of Indicators:**

*   **MRI:** The MRI of 0.8 suggests a medium level of risk, making it a moderate investment at the time of the measurement.
*   **RSI:**  The RSI is extremely high (96.52), indicating that the stock is significantly overbought. This often suggests a potential pullback or correction.
*   **PPO:** The PPO (Percentage Price Oscillator) is at 0.66, indicating positive momentum.
*   **Hybrid Signal:** The hybrid signal suggests buying and holding.
*   **Recent Relative Divergence Change:** The 20-day increase in relative divergence indicates short-term outperformance compared to the S&P 500 in this specific timeframe.
*   **Expected Return:** The significantly negative expected return of -44.8% is alarming and suggests a pessimistic outlook for JNJ compared to the S&P 500 over the long term.

**4. Recent News & Significant Events**

*   **Strong Earnings and Strategic Acquisition:** Positive news regarding strong earnings and a strategic acquisition contributed to a recent surge in stock price. (Source: NAI500)
*   **New Cancer Specialist Acquisition:** J&J acquired a new cancer specialist for $3.05 billion. This is a significant investment in the oncology sector. (Source: Investor's Business Daily)
*   **Positive Phase 3b TREMFYA® Arthritis Data:** Positive clinical trial data for TREMFYA® may have a positive impact on valuation. (Source: simplywall.st)
*   **Analyst Sentiment Mixed:**  Reports vary on analyst sentiment. (Source: Yahoo Finance, MarketBeat)

**4-2. Analyst Opinions**

*   **Consensus:** Buy (Mean: 2.16)
*   **Target Price:** Average: 200.82, High: 230.00, Low: 155.00

**Analysis of Analyst Opinions:** The analyst consensus leans towards a "Buy" rating, but the target price range is wide, suggesting some uncertainty. The average target price is slightly below the current price, indicating that analysts may not expect significant near-term price appreciation.

**5. Recent Earnings Analysis**

| 날짜       | EPS  | 매출     |
|------------|------|----------|
| 2025-10-22 | 2.14 | 23.99 B$ |
| 2025-07-24 | 2.3  | 23.74 B$ |
| 2025-04-23 | 4.57 | 21.89 B$ |
| 2024-10-23 | 1.12 | 22.47 B$ |
| 2025-10-22 | 1.12 | 22.47 B$ |

**Analysis of Earnings:**
*   Revenue figures remain relatively stable, with some increase between 2024 and 2025.
*   EPS (Earnings per Share) varies significantly between quarters. The 2025-04-23 numbers are high, while 2024-10-23 and 2025-10-22 numbers are significantly lower. The reason behind such fluctuation would be interesting to analyze.

**6. Financial Information**

**Revenue and Profitability:**

| Quarter      | Revenue    | Profit Margin |
|--------------|------------|---------------|
| 2025-09-30   | $23.99B    | 69.56%        |
| 2025-06-30   | $23.74B    | 67.87%        |
| 2025-03-31   | $21.89B    | 66.40%        |
| 2024-12-31   | $22.52B    | 68.35%        |
| 2024-09-30   | $22.47B    | 69.01%        |

**Capital and Profitability:**

| Quarter      | Equity     | ROE    |
|--------------|------------|--------|
| 2025-09-30   | $79.28B    | 6.50%  |
| 2025-06-30   | $78.47B    | 7.06%  |
| 2025-03-31   | $78.11B    | 14.08% |
| 2024-12-31   | $71.49B    | 4.80%  |
| 2024-09-30   | $70.16B    | 3.84%  |

**Analysis of Financials:**

*   **Revenue:** Revenue has shown a steady, but not spectacular, increase over the past year.
*   **Profit Margin:**  The profit margin is very high, consistently above 66%, which is a positive sign of efficiency and pricing power.
*   **Equity:** Equity has been increasing steadily over the periods observed.
*   **ROE:** The Return on Equity (ROE) is volatile, with a high spike in 2025-03-31. Generally, the ROE is decent, but the volatility warrants further investigation.

**7. Comprehensive Analysis**

*   **Underperformance:** JNJ has underperformed the S&P 500 significantly in the long term.
*   **Recent Positive Momentum:**  Recently, there has been some positive momentum due to strong earnings, strategic acquisitions, and positive clinical trial data. This is reflected in the short-term price action and the relative divergence change.
*   **Overbought Condition:** The RSI indicates that the stock is currently overbought and might be due for a correction.
*   **Analyst Sentiment:** Analyst opinions are mixed, with a consensus "Buy" but a wide range of target prices.
*   **Solid Financials:** JNJ has strong financials with high profit margins and increasing equity.
*   **Earnings Volatility:** EPS exhibits significant fluctuation.

**Conclusion:**

JNJ appears to be a company with solid fundamentals and a high profit margin. It has also shown great stock increases in revenue figures. The stock's underperformance compared to the broader market and the negative expected return are causes for concern. The current overbought condition, as indicated by the high RSI, and low Beta suggests that future returns could be low. Recent positive news has driven the stock price up, but it remains to be seen if this momentum can be sustained. The analyst consensus suggests a "Buy," but investors should carefully consider the wide range of target prices and the company's recent underperformance before making a decision.


**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.